目的：研究应用肿瘤来源的热休克蛋白70治疗后荷瘤小鼠外周血中几种主要Th1型细胞因子水平的动态变化，探讨其打破荷瘤机体的免疫耐受、诱导抗肿瘤免疫的机制，为其应用于治疗人类的恶性肿瘤提供有价值的参考依据。方法：细胞培养、蛋白质纯化技术、电泳技术、Western-blot法、毛细管电泳、动物实验、ELISA等。结果：肿瘤来源的热休克蛋白70具有明显的抑瘤作用，并且能够诱升荷瘤小鼠外周血中几种主要的Th1型细胞因子(IL-2,TNF-β,IFN-γ)的水平，随HSP70的应用频次增加而逐渐升高，在最后治疗的2周后仍未见下降趋势，与对照组相比，差异显著 (P<0.01）。结论:肿瘤来源的HSP70对荷瘤小鼠Th1型细胞因子有明确的诱升作用，进而诱导机体产生并维持有效的抗肿瘤免疫效应，该作用是其抗肿瘤免疫效应的一个重要方面。

Objective: To investigate the successive fluctuation of some Th1 type cytokines in the peripheral blood of tumor-bearing mice treated with tumor-derived heat shock protein 70(HSP70), explore the mechanism of HSP 70 in breaking through the tumor-immunity tolerance of the organism with tumor-burden and in inducing effective anti-tumor immune response, and provide valuable reference for tumor-derived HSP70 administration in treating human cancer. Methods:Cell culture, techniques for protein extraction and purification, SDS-PAGE, Western-blot, capillary electrophoresis, ELISA technique and animal experiment were applied. Results: HSP70 could result in apparent tumor-inhibitory effect and upregulate some Th1 type cytokines(IL-2, TNF-β, and IFN-γ) in the peripheral blood of the treated mice gradually to the frequency of HSP70 administration, and showed no reduction trend in two weeks after the final treatment. Statistically significant difference was observed contrasted with those of the control group (P<0.01).Conclusion: Tumor-derived HSP70 could dramatically upregulate the Th1 type cytokines of tumor-bearing mice to trigger and maintain effective immunological activity against tumor, which is an important aspect of its anti tumor activity.

沈阳市科委社发基金项目资助20004903200